Abstract：
The use of cannabis and cannabis-related products among patients with hidradenitis suppurativa (HS) is increasing globally. Given the potential anti-inflammatory, therapeutic, and pain management benefits of cannabis-related products, we reviewed primary literature to evaluate the prevalence and possible purpose for cannabis use among patients with HS and to provide recommendations to patients and physicians. A narrative review of original studies was conducted using Embase and Ovid Medline databases. The search strategy was confirmed by a librarian and conducted on September 1, 2023, using a detailed list of subject headings and keywords tailored to cannabis, cannabis-related products, HS, and both adult and pediatric populations. Among 43 identified studies, 6 met the eligibility criteria and encompassed 34,435 patients. Patients were mostly female, and studies were conducted across the United States, Canada, and France. Findings show higher cannabis use among HS patients, demonstrating efficacy in pain management, sleep, anxiety relief, itch relief, and improved quality of life. Cannabis may play a role in analgesia, improved quality of life, pain, itch, and overall mental health in patients with HS and healthcare providers including dermatologists should increase their familiarity in appropriate use of cannabis-related products.
摘要：
在全球范围内，化脓性汗腺炎（HS）患者中大麻和大麻相关产品的使用正在增加。考虑到潜在的抗炎作用,治疗性的,以及大麻相关产品的疼痛管理益处，我们回顾了主要文献,以评估HS患者使用大麻的患病率和可能目的,并向患者和医师提供建议.使用Embase和OvidMedline数据库对原始研究进行了叙述性审查。该搜索策略得到了图书馆员的确认，并于2023年9月1日进行，使用了针对大麻量身定制的主题标题和关键字的详细列表，大麻相关产品,HS,以及成人和儿科人群。在43项确定的研究中，6符合资格标准，涵盖34,435名患者。患者大多是女性，研究在美国各地进行，加拿大,和法国。研究结果表明，HS患者使用大麻的比例更高，证明疼痛管理的有效性，睡眠,缓解焦虑,瘙痒缓解,提高了生活质量。大麻可能在镇痛中起作用，提高生活质量,疼痛,痒,HS患者的总体心理健康和包括皮肤科医生在内的医疗保健提供者应增加他们对适当使用大麻相关产品的熟悉度。
